TY - JOUR
T1 - Soy-isoflavone-enriched foods and markers of lipid and glucose metabolism in postmenopausal women
T2 - Interactions with genotype and equol production
AU - Hall, Wendy L.
AU - Vafeiadou, Katerina
AU - Hallund, Jesper
AU - Bugel, Susanne
AU - Reimann, Manja
AU - Koebnick, Corinna
AU - Zunft, H. J.Franz
AU - Ferrari, Marika
AU - Branca, Francesco
AU - Dadd, Tony
AU - Talbot, Duncan
AU - Powell, Jonathan
AU - Minihane, Anne Marie
AU - Cassidy, Aedin
AU - Nilsson, Maria
AU - Dahlman-Wright, Karin
AU - Gustafsson, Jan Åke
AU - Williams, Christine M.
N1 - Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2006/3/1
Y1 - 2006/3/1
N2 - Background: The hypocholesterolemic effects of soy foods are well established, and it has been suggested that isoflavones are responsible for this effect. However, beneficial effects of isolated isoflavones on lipid biomarkers of cardiovascular disease risk have not yet been shown. Objective: The objective was to investigate the effects of isolated soy isoflavones on metabolic biomarkers of cardiovascular disease risk, including plasma total, HDL, and LDL cholesterol; triacylglycerols; lipoprotein(a); the percentage of small dense LDL; glucose; nonesterified fatty acids; insulin; and the homeostasis model assessment of insulin resistance. Differences with respect to single nucleotide polymorphisms in selected genes [ie, estrogen receptor α (XbaI and PvuII), estrogen receptor β (AluI), and estrogen receptor β(cx) (Tsp509I), endothelial nitric oxide synthase (Glu298Asp), apolipoprotein E (Apo E2, E3, and E4), cholesteryl ester transfer protein (TaqIB), and leptin receptor (Gln223Arg)] and with respect to equol production were investigated. Design: Healthy postmenopausal women (n = 117) participated in a randomized, double-blind, placebo-controlled, crossover dietary intervention trial. Isoflavone-enriched (genistein-to-daidzein ratio of 2:1; 50 mg/d) or placebo cereal bars were consumed for 8 wk, with a wash-out period of 8 wk before the crossover. Results: Isoflavones did not have a significant beneficial effect on plasma concentrations of lipids, glucose, or insulin. A significant difference between the responses of HDL cholesterol to isoflavones and to placebo was found with estrogen receptor β(cx) Tsp509I genotype AA, but not GG or GA. Conclusions: Isoflavone supplementation, when provided in the form and dose used in this study, had no effect on lipid or other metabolic biomarkers of cardiovascular disease risk in postmenopausal women but may increase HDL cholesterol in an estrogen receptor β gene-polymorphic subgroup.
AB - Background: The hypocholesterolemic effects of soy foods are well established, and it has been suggested that isoflavones are responsible for this effect. However, beneficial effects of isolated isoflavones on lipid biomarkers of cardiovascular disease risk have not yet been shown. Objective: The objective was to investigate the effects of isolated soy isoflavones on metabolic biomarkers of cardiovascular disease risk, including plasma total, HDL, and LDL cholesterol; triacylglycerols; lipoprotein(a); the percentage of small dense LDL; glucose; nonesterified fatty acids; insulin; and the homeostasis model assessment of insulin resistance. Differences with respect to single nucleotide polymorphisms in selected genes [ie, estrogen receptor α (XbaI and PvuII), estrogen receptor β (AluI), and estrogen receptor β(cx) (Tsp509I), endothelial nitric oxide synthase (Glu298Asp), apolipoprotein E (Apo E2, E3, and E4), cholesteryl ester transfer protein (TaqIB), and leptin receptor (Gln223Arg)] and with respect to equol production were investigated. Design: Healthy postmenopausal women (n = 117) participated in a randomized, double-blind, placebo-controlled, crossover dietary intervention trial. Isoflavone-enriched (genistein-to-daidzein ratio of 2:1; 50 mg/d) or placebo cereal bars were consumed for 8 wk, with a wash-out period of 8 wk before the crossover. Results: Isoflavones did not have a significant beneficial effect on plasma concentrations of lipids, glucose, or insulin. A significant difference between the responses of HDL cholesterol to isoflavones and to placebo was found with estrogen receptor β(cx) Tsp509I genotype AA, but not GG or GA. Conclusions: Isoflavone supplementation, when provided in the form and dose used in this study, had no effect on lipid or other metabolic biomarkers of cardiovascular disease risk in postmenopausal women but may increase HDL cholesterol in an estrogen receptor β gene-polymorphic subgroup.
KW - Cardiovascular disease
KW - Cholesterol
KW - Estrogen receptor
KW - Gene-nutrient interaction
KW - Glucose
KW - Insulin
KW - Isoflavones
KW - Plasma lipids
KW - Postmenopausal women
KW - Soy
KW - Triacylglycerols
UR - http://www.scopus.com/inward/record.url?scp=33645641438&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33645641438&partnerID=8YFLogxK
U2 - 10.1093/ajcn.83.3.592
DO - 10.1093/ajcn.83.3.592
M3 - Article
C2 - 16522905
AN - SCOPUS:33645641438
SN - 0002-9165
VL - 83
SP - 592
EP - 600
JO - American Journal of Clinical Nutrition
JF - American Journal of Clinical Nutrition
IS - 3
ER -